Alimetry Limited is a company that designs, manufactures, and markets wearable medical devices to aid in the diagnosis of gastric dysfunction.
Alimetry was founded in 2019 in New Zealand by Professor Greg O’Grady and Dr. Armen Gharibans. The company is a spin-out of the University of Auckland’s Bioengineering Institute.
This company raised its first round of capital in December 2020. In March 2022, They announced a Series A raise of NZD $16.3 million. The round was led by investment fund Movac, alongside existing investors UniServices, IP Group, and Matū Karihi. K1W1 also participated in the round.
They are US-based subsidiary, called Alimetry Inc., which was founded in 2022. The subsidiary is based in Minneapolis, MN.
Alimetry’s first product is called Gastric Alimetry, and it is a non-invasive, wearable device that records electrophysiological data from the stomach alongside patient-reported symptoms such as nausea, vomiting, abdominal pain, and bloating.
The output of the test is a report that clinicians can use to assist with the diagnosis of chronic nausea and vomiting disorders such as Gastroparesis.
Gastric Alimetry received FDA approval and UKCA marking in 2022. The device is currently available for use in the USA, UK, and New Zealand.